1. Home
  2. CCEL vs BRNS Comparison

CCEL vs BRNS Comparison

Compare CCEL & BRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cryo-Cell International Inc.

CCEL

Cryo-Cell International Inc.

HOLD

Current Price

$3.46

Market Cap

27.8M

Sector

Health Care

ML Signal

HOLD

Logo Barinthus Biotherapeutics plc

BRNS

Barinthus Biotherapeutics plc

HOLD

Current Price

$0.69

Market Cap

24.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CCEL
BRNS
Founded
1989
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Managed Health Care
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
27.8M
24.1M
IPO Year
2022
2021

Fundamental Metrics

Financial Performance
Metric
CCEL
BRNS
Price
$3.46
$0.69
Analyst Decision
Hold
Strong Buy
Analyst Count
1
1
Target Price
N/A
$4.00
AVG Volume (30 Days)
7.5K
21.2K
Earning Date
04-14-2026
05-07-2026
Dividend Yield
4.26%
N/A
EPS Growth
N/A
N/A
EPS
0.01
N/A
Revenue
$25,384,279.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$344.00
N/A
Revenue Growth
9.76
N/A
52 Week Low
$2.72
$0.51
52 Week High
$5.52
$2.91

Technical Indicators

Market Signals
Indicator
CCEL
BRNS
Relative Strength Index (RSI) 46.48 56.66
Support Level $3.18 $0.66
Resistance Level $3.57 $0.75
Average True Range (ATR) 0.19 0.06
MACD -0.02 0.00
Stochastic Oscillator 6.12 57.43

Price Performance

Historical Comparison
CCEL
BRNS

About CCEL Cryo-Cell International Inc.

Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.

About BRNS Barinthus Biotherapeutics plc

Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease. It is also developing VTP-300 for chronic hepatitis B using viral vector platform technologies, aimed at inducing disease-specific immune responses.

Share on Social Networks: